Background: Esophageal squamous cell carcinoma(ESCC) is a leading cause of cancer?related death, and new prognostic biomarkers are urgently needed. Apoptosis?stimulating P53?binding protein 1(ASPP1) and 2(ASPP2) have ...Background: Esophageal squamous cell carcinoma(ESCC) is a leading cause of cancer?related death, and new prognostic biomarkers are urgently needed. Apoptosis?stimulating P53?binding protein 1(ASPP1) and 2(ASPP2) have been reported to play important roles in the development, progression, metastasis, and prognosis of cancers, but their roles in ESCC have not been elucidated. In this study, we examined the expression of ASPP1 and ASPP2 in ESCC to evaluate their prognostic values.Methods: The protein expression of ASPP1, ASPP2, and P53 in 175 specimens of ESCC was detected using immuno?histochemical staining; their expression in cancerous and noncancerous tissues was scored according to the stain?ing intensity and the percentage of stained cells. The associations of ASPP1, ASPP2, and P53 with clinicopathologic parameters, overall survival(OS), and disease?free survival(DFS) were analyzed.Results: The protein expression levels of ASPP2 and P53 were significantly higher in cancerous tissues than in paired noncancerous tissues(P < 0.001), whereas the expression levels of ASPP1 in the two groups were similar. In ESCCs, ASPP1 expression was significantly associated with histological differentiation(P = 0.002) and invasive depth(P = 0.014); ASPP2 expression was associated with age(P = 0.029) and histological differentiation(P < 0.001); and P53 expression was associated with age(P and P53 expression. Survival an= 0.021) and tumor size(P alysis revealed that high AS= 0.040). No correlations were found between ASPP1, ASPP2,PP2 expression was significantly associated with increased 5?year OS(P = 0.001) and DFS rates(P ate of ESCC patients(= 0.010) and that high P53 expression was significantly associated with a reduced 5?year DFS rP atio(HR): 0.541, 9= 0.015). Multivariate Cox analysis indicated that ASPP2 was an inde?pendent predictor of OS [hazard r5% confidence interval(CI) 0.363–0.804] and DFS(HR: 0.599, 95% CI 0.404–0.888) of ESCC patients and that P53 was an independent predictor of DFS(HR: 2.161, 95% CI 1.100–4.245).Conclusions: ASPP1 might be involved in the progression of ESCC, and ASPP2 was a potential prognostic biomarker of ESCC and should be evaluated in future studies.展开更多
背景:p53基因是一种关键的肿瘤抑制基因,最初因在调控细胞周期、DNA修复及凋亡中的核心作用而被广泛研究。近年来,研究发现p53在肌肉骨骼疾病中同样发挥重要作用,p53的异常表达和功能失调被认为是这些疾病发生和发展的重要因素,但具体...背景:p53基因是一种关键的肿瘤抑制基因,最初因在调控细胞周期、DNA修复及凋亡中的核心作用而被广泛研究。近年来,研究发现p53在肌肉骨骼疾病中同样发挥重要作用,p53的异常表达和功能失调被认为是这些疾病发生和发展的重要因素,但具体作用机制及临床转化潜力尚未系统阐明。目的:综述p53在肌肉骨骼疾病中的多重作用,分析p53影响疾病进展的分子机制,并评估p53作为跨疾病治疗靶点的潜力。方法:通过检索PubMed数据库2004年1月至2024年12月的文献,以“P53,Osteoporosis,Post-Menopausal Osteoporosis,Osteoarthritis,Degenerative Arthritis,Rheumatoid Arthritis,Gout,Low Back Pains,Low Back Ache,Back Pain,Scoliosis”为检索词,纳入原始研究、综述及临床试验等文献,排除非英文文献及无关机制研究,最终筛选81篇文献进行综合分析。结果与结论:p53通过调控成骨-破骨平衡(如p53-Nedd4-Runx2轴)、软骨细胞凋亡(如miR-34a-SIRT1-p53通路)、炎症递质(如肿瘤坏死因子α/白细胞介素6)及氧化应激(如p53-SLC2A9轴)等机制,参与肌肉骨骼疾病的发生发展。p53的双向作用(促凋亡与抗炎)提示需精准调控p53活性。基于基因编辑(如CRISPR/Cas9)、小分子抑制剂(如PFT-α)及天然产物(如柚皮苷)的干预策略展现出治疗潜力,但临床转化仍需进一步验证。未来需结合多学科技术深化p53机制研究与临床实践。展开更多
基金supported by grants from the Research Fund of Guangdong Esophageal Cancer Institute of China(Grant No:M201412 for H-YW)the Research Fund of the State Key Laboratory of Oncology in South China(to H-YW)
文摘Background: Esophageal squamous cell carcinoma(ESCC) is a leading cause of cancer?related death, and new prognostic biomarkers are urgently needed. Apoptosis?stimulating P53?binding protein 1(ASPP1) and 2(ASPP2) have been reported to play important roles in the development, progression, metastasis, and prognosis of cancers, but their roles in ESCC have not been elucidated. In this study, we examined the expression of ASPP1 and ASPP2 in ESCC to evaluate their prognostic values.Methods: The protein expression of ASPP1, ASPP2, and P53 in 175 specimens of ESCC was detected using immuno?histochemical staining; their expression in cancerous and noncancerous tissues was scored according to the stain?ing intensity and the percentage of stained cells. The associations of ASPP1, ASPP2, and P53 with clinicopathologic parameters, overall survival(OS), and disease?free survival(DFS) were analyzed.Results: The protein expression levels of ASPP2 and P53 were significantly higher in cancerous tissues than in paired noncancerous tissues(P < 0.001), whereas the expression levels of ASPP1 in the two groups were similar. In ESCCs, ASPP1 expression was significantly associated with histological differentiation(P = 0.002) and invasive depth(P = 0.014); ASPP2 expression was associated with age(P = 0.029) and histological differentiation(P < 0.001); and P53 expression was associated with age(P and P53 expression. Survival an= 0.021) and tumor size(P alysis revealed that high AS= 0.040). No correlations were found between ASPP1, ASPP2,PP2 expression was significantly associated with increased 5?year OS(P = 0.001) and DFS rates(P ate of ESCC patients(= 0.010) and that high P53 expression was significantly associated with a reduced 5?year DFS rP atio(HR): 0.541, 9= 0.015). Multivariate Cox analysis indicated that ASPP2 was an inde?pendent predictor of OS [hazard r5% confidence interval(CI) 0.363–0.804] and DFS(HR: 0.599, 95% CI 0.404–0.888) of ESCC patients and that P53 was an independent predictor of DFS(HR: 2.161, 95% CI 1.100–4.245).Conclusions: ASPP1 might be involved in the progression of ESCC, and ASPP2 was a potential prognostic biomarker of ESCC and should be evaluated in future studies.
文摘背景:p53基因是一种关键的肿瘤抑制基因,最初因在调控细胞周期、DNA修复及凋亡中的核心作用而被广泛研究。近年来,研究发现p53在肌肉骨骼疾病中同样发挥重要作用,p53的异常表达和功能失调被认为是这些疾病发生和发展的重要因素,但具体作用机制及临床转化潜力尚未系统阐明。目的:综述p53在肌肉骨骼疾病中的多重作用,分析p53影响疾病进展的分子机制,并评估p53作为跨疾病治疗靶点的潜力。方法:通过检索PubMed数据库2004年1月至2024年12月的文献,以“P53,Osteoporosis,Post-Menopausal Osteoporosis,Osteoarthritis,Degenerative Arthritis,Rheumatoid Arthritis,Gout,Low Back Pains,Low Back Ache,Back Pain,Scoliosis”为检索词,纳入原始研究、综述及临床试验等文献,排除非英文文献及无关机制研究,最终筛选81篇文献进行综合分析。结果与结论:p53通过调控成骨-破骨平衡(如p53-Nedd4-Runx2轴)、软骨细胞凋亡(如miR-34a-SIRT1-p53通路)、炎症递质(如肿瘤坏死因子α/白细胞介素6)及氧化应激(如p53-SLC2A9轴)等机制,参与肌肉骨骼疾病的发生发展。p53的双向作用(促凋亡与抗炎)提示需精准调控p53活性。基于基因编辑(如CRISPR/Cas9)、小分子抑制剂(如PFT-α)及天然产物(如柚皮苷)的干预策略展现出治疗潜力,但临床转化仍需进一步验证。未来需结合多学科技术深化p53机制研究与临床实践。
